In Vitro α-Glucosidase and α-Amylase Inhibition, Cytotoxicity and Free Radical Scavenging Profiling of the 6-Halogeno and Mixed 6,8-Dihalogenated 2-Aryl-4-methyl-1,2-dihydroquinazoline 3-Oxides

Overview

Journal Antioxidants (Basel)

Date 2023 Nov 25

PMID 38001824

Authors

Nontokozo M Magwaza

Garland K More

Samantha Gildenhuys

Malose J Mphahlele

Affiliations

Soon will be listed here.

Abstract

Series of the 6-bromo/iodo substituted 2-aryl-4-methyl-1,2-dihydroquinazoline-3-oxides and their mixed 6,8-dihalogenated (Br/I and I/Br) derivatives were evaluated for inhibitory properties against α-glucosidase and/or α-amylase activities and for cytotoxicity against breast (MCF-7) and lung (A549) cancer cell lines. The 6-bromo-2-phenyl substituted and its corresponding 6-bromo-8-iodo-2-phenyl-substituted derivative exhibited dual activity against α-glucosidase (IC = 1.08 ± 0.02 μM and 1.01 ± 0.05 μM, respectively) and α-amylase (IC = 5.33 ± 0.01 μM and 1.18 ± 0.06 μM, respectively) compared to acarbose (IC = 4.40 ± 0.05 μM and 2.92 ± 0.02 μM, respectively). The 6-iodo-2-(4-fluorophenyl)-substituted derivative , on the other hand, exhibited strong activity against α-amylase and significant inhibitory effect against α-glucosidase with IC values of 0.64 ± 0.01 μM and 9.27 ± 0.02 μM, respectively. Compounds , and exhibited the highest activity against α-glucosidase with IC values of 1.04 ± 0.03, 0.92 ± 0.01 and 0.78 ± 0.05 μM, respectively. Moderate cytotoxicity against the MCF-7 and A549 cell lines was observed for these compounds compared to the anticancer drugs doxorubicin (IC = 0.25 ± 0.05 μM and 0.36 ± 0.07 μM, respectively) and gefitinib (IC = 0.19 ± 0.04 μM and 0.25 ± 0.03 μM, respectively), and their IC values are in the range of 10.38 ± 0.08-25.48 ± 0.08 μM and 11.39 ± 0.12-20.00 ± 0.05 μM, respectively. The test compounds generally exhibited moderate to strong antioxidant capabilities, as demonstrated via robust free radical scavenging activity assays, viz., DPPH and NO. The potential of selected derivatives to inhibit superoxide dismutase (SOD) was also investigated via enzymatic assay in vitro. Molecular docking revealed the N-O moiety as essential to facilitate electrostatic interactions of the test compounds with the protein residues in the active site of α-glucosidase and α-amylase. The presence of bromine and/or iodine atoms resulted in increased hydrophobic (alkyl and/or π-alkyl) interactions and therefore increased inhibitory effect against both enzymes.

References

Song F, Xu G, Gaul M, Zhao B, Lu T, Zhang R . Design, synthesis and structure activity relationships of indazole and indole derivatives as potent glucagon receptor antagonists. Bioorg Med Chem Lett. 2019; 29(15):1974-1980. DOI: 10.1016/j.bmcl.2019.05.036. View

Mphahlele M, Magwaza N, Gildenhuys S, Setshedi I . Synthesis, α-glucosidase inhibition and antioxidant activity of the 7-carbo-substituted 5-bromo-3-methylindazoles. Bioorg Chem. 2020; 97:103702. DOI: 10.1016/j.bioorg.2020.103702. View

Lu Y, Wang Y, Zhu W . Nonbonding interactions of organic halogens in biological systems: implications for drug discovery and biomolecular design. Phys Chem Chem Phys. 2010; 12(18):4543-51. DOI: 10.1039/b926326h. View

Spek A . Structure validation in chemical crystallography. Acta Crystallogr D Biol Crystallogr. 2009; 65(Pt 2):148-55. PMC: 2631630. DOI: 10.1107/S090744490804362X. View

Sheldrick G . SHELXT - integrated space-group and crystal-structure determination. Acta Crystallogr A Found Adv. 2014; 71(Pt 1):3-8. PMC: 4283466. DOI: 10.1107/S2053273314026370. View

Petrov S, Yusubov M, Beloglazkina E, Nenajdenko V . Synthesis of Radioiodinated Compounds. Classical Approaches and Achievements of Recent Years. Int J Mol Sci. 2022; 23(22). PMC: 9698107. DOI: 10.3390/ijms232213789. View

Cavina L, van der Born D, Klaren P, Feiters M, Boerman O, Rutjes F . Design of Radioiodinated Pharmaceuticals: Structural Features Affecting Metabolic Stability towards in Vivo Deiodination. European J Org Chem. 2017; 2017(24):3387-3414. PMC: 5499721. DOI: 10.1002/ejoc.201601638. View

Hernandes M, Cavalcanti S, Moreira D, de Azevedo Junior W, Lima Leite A . Halogen atoms in the modern medicinal chemistry: hints for the drug design. Curr Drug Targets. 2010; 11(3):303-14. DOI: 10.2174/138945010790711996. View

Lu Y, Liu Y, Xu Z, Li H, Liu H, Zhu W . Halogen bonding for rational drug design and new drug discovery. Expert Opin Drug Discov. 2012; 7(5):375-83. DOI: 10.1517/17460441.2012.678829. View

10.

Mikiciuk-Olasik E, Baszczak-Swiatkiewiz K, Zurek E, Krajewska U, Rozalski M, Kruszynski R . New derivatives of quinazoline and 1, 2-dihydroquinazoline n3-oxide with expected antitumor activity. Arch Pharm (Weinheim). 2004; 337(5):239-46. DOI: 10.1002/ardp.200100656. View

11.

Shao J, Kuiper B, Thunnissen A, Cool R, Zhou L, Huang C . The Role of Tryptophan in π Interactions in Proteins: An Experimental Approach. J Am Chem Soc. 2022; 144(30):13815-13822. PMC: 9354243. DOI: 10.1021/jacs.2c04986. View

12.

Younus H . Therapeutic potentials of superoxide dismutase. Int J Health Sci (Qassim). 2018; 12(3):88-93. PMC: 5969776. View

13.

Sharma C, Kaur A, Thind S, Singh B, Raina S . Advanced glycation End-products (AGEs): an emerging concern for processed food industries. J Food Sci Technol. 2015; 52(12):7561-76. PMC: 4648888. DOI: 10.1007/s13197-015-1851-y. View

14.

Combs D, Rampulla M, Russell R, Rampulla R, Klaubert D, Ritchie D . Design, synthesis and bronchodilatory activity of a series of quinazoline-3-oxides. Drug Des Deliv. 1990; 6(4):241-54. View

15.

Hobbs A, Higgs A, Moncada S . Inhibition of nitric oxide synthase as a potential therapeutic target. Annu Rev Pharmacol Toxicol. 1999; 39:191-220. DOI: 10.1146/annurev.pharmtox.39.1.191. View

16.

Rydberg E, Li C, Maurus R, Overall C, Brayer G, Withers S . Mechanistic analyses of catalysis in human pancreatic alpha-amylase: detailed kinetic and structural studies of mutants of three conserved carboxylic acids. Biochemistry. 2002; 41(13):4492-502. DOI: 10.1021/bi011821z. View

17.

Pili R, Chang J, Partis R, Mueller R, Chrest F, Passaniti A . The alpha-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis, and inhibits tumor growth. Cancer Res. 1995; 55(13):2920-6. View

18.

Pathare R, Maurya A, Kumari A, Agnihotri V, Verma V, Sawant D . Synthesis of quinazoline-3-oxides via a Pd(ii) catalyzed azide-isocyanide coupling/cyclocondensation reaction. Org Biomol Chem. 2018; 17(2):363-368. DOI: 10.1039/c8ob02627k. View

19.

Stuehr D, Fasehun O, Kwon N, Gross S, Gonzalez J, Levi R . Inhibition of macrophage and endothelial cell nitric oxide synthase by diphenyleneiodonium and its analogs. FASEB J. 1991; 5(1):98-103. DOI: 10.1096/fasebj.5.1.1703974. View

20.

Tiz D, Bagnoli L, Rosati O, Marini F, Sancineto L, Santi C . New Halogen-Containing Drugs Approved by FDA in 2021: An Overview on Their Syntheses and Pharmaceutical Use. Molecules. 2022; 27(5). PMC: 8912053. DOI: 10.3390/molecules27051643. View